Using Analytics to Gain Insights on U.S. Prescription Drug Prices: An Inductive Analysis

Using data scraping techniques to gather data from a variety of previously disjointed sources—some proprietary and some publicly available—this research applies the analytical techniques of data visualization and machine learning to (1) gain exploratory insights into the drivers of prescription drug list prices and (2) test how well these variables impact prices directly and interact to predict pricing. Specifically, this inductive analysis considers characteristics related to the brand (i.e., manufacturer, brand/generic classification), product attributes (i.e., dosing levels, amount of active ingredient), the condition for which the drug is recommended (i.e., therapeutic class, subclass, and pricing tier), and market factors (i.e., number of drugs in class and approval year). Through these analytic analyses, the authors seek to cut through some of the opacity of pharmaceutical drug list prices to consider the drivers of drug prices, evaluate how these insights might drive marketplace and policy solutions, and spark future research inquiries in this area.

[1]  Milton S. Boyd,et al.  Designing a neural network for forecasting financial and economic time series , 1996, Neurocomputing.

[2]  B. Jönsson Flat or monotonic pricing of pharmaceuticals: practice and consequences , 2001, The European Journal of Health Economics (HEPAC).

[3]  Anne Mahoney,et al.  Comparing drug classification systems. , 2008, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[4]  Kenneth C. Frazier Affording Medicines for Today's Patients and Sustaining Innovation for Tomorrow. , 2020, JAMA.

[5]  E. Topol,et al.  Trends in Prices of Popular Brand-Name Prescription Drugs in the United States , 2019, JAMA network open.

[6]  K. Fairman,et al.  What Is the Price Benchmark to Replace Average Wholesale Price (AWP)? , 2010, Journal of managed care pharmacy : JMCP.

[7]  H S Khamis,et al.  APPLICATION OF k- NEAREST NEIGHBOUR CLASSIFICATION IN MEDICAL DATA MINING IN THE CONTEXT OF KENYA , 2014 .

[8]  Kathleen M. Iacocca,et al.  Cooperative partnerships and pricing in the pharmaceutical supply chain , 2018, Int. J. Prod. Res..

[9]  D. Salkever,et al.  "Generic Entry and the Pricing of Pharmaceuticals" , 1995 .

[10]  Alex M. Azar Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees , 2019 .

[11]  E. Taylor,et al.  Drug pricing and value in oncology. , 2010, The oncologist.

[12]  R. Temple,et al.  Therapeutic-class wars--drug promotion in a competitive marketplace. , 1994, The New England journal of medicine.

[13]  Isao Kamae,et al.  Defining the concept of fair pricing for medicines , 2020, BMJ.

[14]  R. C. Campbell,et al.  Do Pharmaceutical Marketing Activities Raise Prices? Evidence from Five Major Therapeutic Classes , 2009 .

[15]  Giles Moss,et al.  How different are branding strategies in the pharmaceutical industry and the fast-moving consumer goods sector? , 2004 .

[16]  Kathleen M. Iacocca,et al.  Why brand drugs priced higher than generic equivalents , 2015 .

[17]  Giles Moss,et al.  A brand logic for pharma : A possible strategy based on FMCG experience , 2004 .

[18]  Carmelo Giaccotto,et al.  Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry* , 2005, The Journal of Law and Economics.

[19]  M. Pauly The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  A. Kesselheim,et al.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. , 2016, JAMA.

[21]  P. Rivers,et al.  Prescription drug spending: contribution to health care spending and cost containment strategies. , 2006, Journal of health care finance.

[22]  Matthew Grennan Price Discrimination and Bargaining: Empirical Evidence from Medical Devices , 2012 .

[23]  J. DiMasi,et al.  New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms , 2000 .

[24]  G. Rasi,et al.  Drug Regulation and Pricing--Can Regulators Influence Affordability? , 2016, The New England journal of medicine.

[25]  Kathleen M. Iacocca,et al.  A multiple regression model to explain the cost of brand-drugs , 2013 .

[26]  Tze-Yun Leong,et al.  Application of K-nearest neighbors algorithm on breast cancer diagnosis problem , 2000, AMIA.

[27]  T. Philipson,et al.  `Me-Too' Innovation in Pharmaceutical Markets , 2009, Forum for health economics & policy.

[28]  W. S. Comanor,et al.  Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.

[29]  Dawn M Gencarelli One pill, many prices: variation in prescription drug prices in selected government programs. , 2005, Issue brief.

[30]  E. Berndt,et al.  Authorized generic drugs, price competition, and consumers' welfare. , 2007, Health affairs.

[31]  Lisa M. Schwartz,et al.  Medical Marketing in the United States, 1997-2016 , 2019, JAMA.